안녕하세요! 저희는 Nemo입니다.
Nemo는 'Never Miss Out(기회를 놓치지 마세요)'의 약자로, 데이터 기반으로 엄선한 투자 아이디어를 손안에서 바로 확인할 수 있는 모바일 투자 플랫폼입니다. 주식, ETF, 암호화폐, CFD를 수수료 없이 거래할 수 있으며, AI 기반 도구, 실시간 시장 알림, 그리고 Nemes라고 불리는 테마별 주식 컬렉션을 제공합니다.
앱 다운로드
QR 코드를 스캔하여 Nemo 앱을 다운로드하고 지금 바로 Nemo에서 투자를 시작하세요
• 5분 읽기
• 2025년 10월 21일 게시
Let’s be honest, for years the global supply chain has felt like a rather precarious game of Jenga. We pull out bits from here, there, and everywhere, hoping the whole tower doesn't come crashing down. Then, a global pandemic came along and gave the table a good, hard shove. Suddenly, the realisation that your nation’s essential medicines are made thousands of miles away didn't seem quite so clever. It seems Merck agrees, and they’re putting a cool £3 billion where their mouth is.
Merck’s plan to build a sprawling new manufacturing plant in Virginia isn't just a line item in an annual report. To me, it’s a flag planted firmly in the ground. It’s a declaration that the old way of doing things, chasing the lowest labour costs across the globe, has run its course. The hidden costs of that model, from shipping delays to geopolitical spats, have finally become too high a price to pay.
This isn't about charity or flag-waving patriotism. It’s a cold, pragmatic calculation. When your supply chain snaps, you don't just lose money, you lose trust. You risk empty pharmacy shelves and public outcry. This investment is an insurance policy, a bet on stability and control in an increasingly unstable world. It’s a recognition that for something as critical as medicine, ‘just in time’ can quickly become ‘not at all’.
Of course, Merck isn’t acting in a vacuum. When a giant like that makes such a move, others are bound to take notice. You can be sure that boardrooms at Pfizer and Eli Lilly are having similar conversations. They have the scale and the resources to follow suit, turning this single investment into a genuine industry-wide shift. This isn't just about one company, it's about rebuilding an entire industrial ecosystem.
This trend creates a fascinating ripple effect for investors. It’s not just the pharmaceutical titans themselves that could stand to benefit. Think about it. Who builds these high-tech facilities? Who supplies the advanced robotics and specialised equipment? Who handles the logistics of a revitalised domestic supply chain? The opportunities spread far and wide. To get a real sense of the scale here, it's worth looking at the bigger picture of Pharma Onshoring: What's Next for US Drug Supply.
For decades, the argument against domestic manufacturing was simple, it was too expensive. That logic is starting to look rather dated. Modern pharmaceutical production is less about armies of workers and more about sophisticated automation. When robots are doing the heavy lifting, the wage difference between Virginia and Shanghai becomes far less important.
What’s more, governments are now sweetening the deal. They see healthcare security as a matter of national security, on par with energy or defence. This means regulatory tailwinds and potential incentives for companies willing to bring production home. Suddenly, the economic equation looks very different. The long-term security and speed to market offered by a domestic facility might just outweigh the short-term cost savings of offshoring. It’s a long game, but it’s one that big pharma now seems determined to play.
전체 바스켓 보기:Pharma Onshoring: What's Next for US Drug Supply
본 기사는 마케팅 자료이며 투자 조언으로 해석되어서는 안 됩니다. 본 기사에 포함된 어떠한 정보도 금융 상품의 매수 또는 매도에 대한 조언, 추천, 제안 또는 권유로 간주되어서는 안 되며, 금융, 투자 또는 거래 조언에 해당하지 않습니다. 특정 금융 상품이나 투자 전략에 대한 언급은 예시 및 교육 목적으로만 제공되며 사전 통지 없이 변경될 수 있습니다. 투자 예정 대상을 평가하고, 본인의 재무 상황을 검토하고, 독립적인 전문가의 조언을 구하는 것은 투자자 본인의 책임입니다. 과거의 성과가 미래의 결과를 보장하지 않습니다. 자세한 내용은 다음 문서를 참조하십시오: 리스크 고지.
2026년 9월 20일 게시
기사 읽기
2026년 9월 20일 게시
기사 읽기
2026년 9월 19일 게시
기사 읽기
2026년 9월 19일 게시
기사 읽기
2026년 9월 18일 게시
기사 읽기
2026년 9월 20일 게시
기사 읽기
2026년 9월 20일 게시
기사 읽기
2026년 9월 19일 게시
기사 읽기
2026년 9월 19일 게시
기사 읽기
2026년 9월 18일 게시
기사 읽기